Comparison of in vitro antibacterial activities of two cationic peptides CM15 and CM11 against five pathogenic bacteria: Pseudomonas aeruginosa, Staphylococcus aureus, Vibrio cholerae, Acinetobacter baumannii, and Escherichia coli

Probiotics and Antimicrobial Proteins
Mehrdad M MoghaddamJ Amani

Abstract

In recent years, the widespread use of antibiotics has caused many bacterial pathogens resistance to conventional antibiotics. Therefore, generation of new antibiotics to control and reduce the effects of these pathogens is urgently needed. Antimicrobial peptides and proteins are important members of the host defense system in eukaryotes. These peptides are potent, broad-spectrum antibiotics that demonstrate potential as novel and alternative therapeutic agents for the treatment of drug-resistant infections. Accordingly, we evaluated two hybrid peptides CM11 (WKLFKKILKVL-NH2) and CM15 (KWKLFKKIGAVLKVL-NH2) on five important pathogenic bacteria. These peptides are short cecropin-melittin hybrid peptides obtained through a sequence combination approach, which are highly effective to inhibit the growth of important pathogenic bacteria. The activity of these two cationic peptides (CM11 and CM15) in different concentrations (2-64 mg/L) was investigated against standard and clinical isolates of important hospital infection bacteria by measuring MIC, MBC, and bactericidal assay. These peptides demonstrated the same ranges of inhibitory values: The organisms in early 24 h were more susceptible to polycationic peptides (MIC: 8 mg/L and ...Continue Reading

References

Nov 1, 1992·International Journal of Peptide and Protein Research·D WadeR B Merrifield
Oct 1, 1991·European Journal of Biochemistry·H G BomanD A Lidholm
May 7, 1990·Biochimica Et Biophysica Acta·C E Dempsey
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·B ChristensenD Mauzerall
Aug 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·M Zasloff
Oct 1, 1986·Biophysical Journal·H Vogel, F Jähnig
Jan 1, 1993·Annual Review of Immunology·R I LehrerT Ganz
Jun 1, 1996·The Journal of Antimicrobial Chemotherapy·A J MooreD A Devine
Nov 9, 2000·Journal of Peptide Science : an Official Publication of the European Peptide Society·L Otvos
Jan 25, 2002·Nature·Michael Zasloff
Nov 26, 2002·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J M Cisneros, J Rodríguez-Baño
Dec 5, 2002·Current Drug Targets. Infectious Disorders·R E W Hancock, A Patrzykat
Mar 5, 2003·Pharmacological Reviews·Michael R Yeaman, Nannette Y Yount
Jul 31, 2003·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Rogerio Hakio KuboyamaMaria Luiza Moretti-Branchini
Aug 22, 2003·Journal of Internal Medicine·H G Boman
Nov 7, 2003·International Journal of Antimicrobial Agents·Kim A BrogdenBrian F Tack
Jun 18, 2004·Immunological Reviews·Philippe BuletLaure Menin
Aug 11, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M Van LooverenUNKNOWN ARPAC Steering Group
Feb 11, 2005·Nature Reviews. Microbiology·Kim A Brogden
Jun 30, 2005·Current Opinion in Infectious Diseases·Shiri Navon-VeneziaYehuda Carmeli
Jul 16, 2005·Current Eye Research·Y Jerold GordonAlison M McDermott
Mar 25, 2006·Expert Opinion on Pharmacotherapy·Lijuan Zhang, Timothy J Falla
Apr 26, 2006·The Journal of Antimicrobial Chemotherapy·María Jesús Rodríguez-HernándezJerónimo Pachón
May 5, 2006·Applied and Environmental Microbiology·Rafael FerreEduard Bardají
Jul 11, 2006·Journal of Molecular Microbiology and Biotechnology·Dorjee G Tamang, Milton H Saier
Jul 19, 2006·Clinical Microbiology Reviews·Håvard JenssenRobert E W Hancock
Aug 22, 2006·Current Medicinal Chemistry·Luca GentilucciFederico Squassabia
Dec 13, 2006·Nature Biotechnology·Robert E W Hancock, Hans-Georg Sahl
Mar 21, 2007·FEMS Microbiology Letters·Emilio Montesinos
Jun 20, 2008·Annals of Clinical Microbiology and Antimicrobials·David C BeanDavid W Wareham
Jan 11, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Catherine LiuHenry F Chambers
Jan 22, 2011·Journal of Medical Microbiology·Maya KitaokaStefan Pukatzki

❮ Previous
Next ❯

Citations

Apr 13, 2015·Journal of Infection and Public Health·Hosseine AghamollaeiNastaran S Barzi
Jul 13, 2017·Journal of Medical Microbiology·Zohreh Mohammadi AzadMehrdad Moosazadeh Moghaddam
Jun 30, 2018·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Hoda MoravejReza Mirnejad
Jan 8, 2020·Biomolecules·Diogo Marcelo Lima RibeiroLuís Cláudio Nascimento da Silva
Mar 3, 2020·Frontiers in Microbiology·Samuele PeppoloniElisabetta Blasi
Aug 30, 2021·Journal of Materials Science. Materials in Medicine·Sadjad KhosravimelalMazaher Gholipourmalekabadi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.